McKay, R. R., Yu, K., Gordoa, T. A., Bono, J. S. D., George, D. J., Hadaschik, B. A., Hansen, A. R., Patel, M. R., Saad, F., Vinceneux, A., Wei, Q., Wu, D. Y. C., Tatarenko, M., Pieters, N., Dibaj, S., Wang, S. C., Capaldi, D. A., Villalobos, V. M., Chatwal, M. S., Sartor, O. (2026). A phase 3 randomized, open-label study of pasritamig (JNJ-78278343), a T-cell engager targeting human kallikrein-2, with docetaxel versus docetaxel for metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps5139